These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26207707)

  • 1. Nivolumab: Immunotherapy in Malignant Melanoma.
    Bayless H; Schneider S
    Clin J Oncol Nurs; 2015 Aug; 19(4):430-2. PubMed ID: 26207707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma.
    Maurice C; Schneider R; Kiehl TR; Bavi P; Roehrl MH; Mason WP; Hogg D
    Cancer Immunol Res; 2015 Dec; 3(12):1299-302. PubMed ID: 26419960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
    Edmondson LA; Smith LV; Mallik A
    J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab.
    Fulchiero E; Jimeno A
    Drugs Today (Barc); 2014 Dec; 50(12):791-802. PubMed ID: 25588084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety of nivolumab for the treatment of metastatic melanoma.
    O'Reilly A; Larkin J
    Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab for Metastatic Melanoma.
    Gupta AK; Daigle D
    Skin Therapy Lett; 2016 Mar; 21(2):6-9. PubMed ID: 27223114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.
    Tanvetyanon T; Creelan BC; Antonia SJ
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):903-10. PubMed ID: 27488231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab in previously untreated melanoma without BRAF mutation.
    Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
    N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab: targeting PD-1 to bolster antitumor immunity.
    Brahmer JR; Hammers H; Lipson EJ
    Future Oncol; 2015; 11(9):1307-26. PubMed ID: 25798726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunotherapy in the treatment of advanced or metastatic melanoma: nivolumab from phase I studies to approvement by European Medicines Agency].
    Queirolo P; Tanda ET
    Recenti Prog Med; 2015 Dec; 106(12):608-17. PubMed ID: 26780070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab.
    Nomura M; Otsuka A; Kondo T; Nagai H; Nonomura Y; Kaku Y; Matsumoto S; Muto M
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):999-1004. PubMed ID: 28983657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.
    Bohensky MA; Pasupathi K; Gorelik A; Kim H; Harrison JP; Liew D
    Value Health; 2016 Dec; 19(8):1009-1015. PubMed ID: 27987627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
    Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
    JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
    Nayar N; Briscoe K; Fernandez Penas P
    J Immunother; 2016 Apr; 39(3):149-52. PubMed ID: 26938948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dramatic Survival Benefit with Nivolumab in Melanoma.
    Cancer Discov; 2016 Jun; 6(6):OF7. PubMed ID: 27091855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.
    Fujimura T; Furudate S; Kakizaki A; Kambayashi Y; Haga T; Hashimoto A; Aiba S
    J Dermatol; 2016 Jun; 43(6):686-9. PubMed ID: 26663262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant melanoma showing a rapid response to nivolumab.
    Tsutsumi M; Asai J; Wada M; Takenaka H; Katoh N
    Australas J Dermatol; 2016 Feb; 57(1):61-3. PubMed ID: 25854419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
    Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.